

Courtney D Thornburg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5108066/publications.pdf>

Version: 2024-02-01

78
papers

1,335
citations

516561

16
h-index

360920

35
g-index

80
all docs

80
docs citations

80
times ranked

1607
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	3.8	37
2	Prepare the Way for Hemophilia A Gene Therapy. New England Journal of Medicine, 2022, 386, 1081-1082.	13.9	6
3	Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 449-460.	0.5	5
4	Results of an international survey on adherence with anticoagulation in children, adolescents, and young adults: Communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	2
5	Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. Pediatrics, 2022, 150, .	1.0	19
6	Neonatal Myocardial Infarction: A Proposed Algorithm for Coronary Arterial Thrombus Management. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011664.	1.4	2
7	Theory-guided assessment of barriers and facilitators to adequate informed consent for childhood cancer clinical trials: Using the Exploration, Preparation, Implementation, Sustainment (EPIS) framework.. Journal of Clinical Oncology, 2022, 40, 6539-6539.	0.8	0
8	Parental informed consent comprehension in childhood cancer clinical trials: Associations with social determinants of health.. Journal of Clinical Oncology, 2022, 40, 6512-6512.	0.8	1
9	Genetic predictors of severe intraventricular hemorrhage in extremely low-birthweight infants. Journal of Perinatology, 2021, 41, 286-294.	0.9	3
10	Characterizing the use of anticoagulants in children using the American Thrombosis and Hemostasis Network Dataset (ATHNdataset). Thrombosis Research, 2021, 197, 84-87.	0.8	9
11	Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opinion on Drug Safety, 2021, 20, 387-396.	1.0	3
12	Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 316-326.	0.5	13
13	Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD. Blood Advances, 2021, 5, 2079-2086.	2.5	4
14	Assessment of Factors Associated With Parental Perceptions of Voluntary Decisions About Child Participation in Leukemia Clinical Trials. JAMA Network Open, 2021, 4, e219038.	2.8	7
15	Improving vitamin D testing and supplementation in children with newly diagnosed cancer: A quality improvement initiative at Rady Children's Hospital San Diego. Pediatric Blood and Cancer, 2021, 68, e29217.	0.8	1
16	Results of the International Survey on Adherence with Anticoagulation in Children, Adolescents and Young Adults. Blood, 2021, 138, 5001-5001.	0.6	0
17	Etranacogene dezaparvovec for hemophilia B gene therapy. Therapeutic Advances in Rare Disease, 2021, 2, 263300402110588.	0.3	3
18	Cost Efficacy of Rapid Whole Genome Sequencing in the Pediatric Intensive Care Unit. Frontiers in Pediatrics, 2021, 9, 809536.	0.9	18

#	ARTICLE	IF	CITATIONS
19	The odds and implications of coinheritance of hemophilia A and B. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 931-935.	1.0	3
20	Improving Pediatric Neuro-Oncology Survival Disparities in the United States-Mexico Border Region: A Cross-Border Initiative Between San Diego, California, and Tijuana, Mexico. JCO Global Oncology, 2020, 6, 1791-1802.	0.8	10
21	Extracellular tyrosyl-tRNA synthetase cleaved by plasma proteinases and stored in platelet granules: Potential role in monocyte activation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1167-1177.	1.0	5
22	Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage. Haemophilia, 2020, 26, e353-e355.	1.0	4
23	Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients. Pediatric Hematology and Oncology, 2020, 37, 314-325.	0.3	8
24	Management and outcomes of pediatric septic thrombophlebitis: a case series. Pediatric Hematology and Oncology, 2020, 37, 344-352.	0.3	7
25	Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank. American Heart Journal, 2020, 224, 138-147.	1.2	0
26	The Evaluation of Hematologic Screening and Perioperative Management in Patients with Noonan Syndrome: A Retrospective Chart Review. Journal of Pediatrics, 2020, 220, 154-158.e6.	0.9	6
27	Athn 15: Characterizing the Real-World Use of Direct Oral Anticoagulants in Pediatric Patients - Interim Analysis. Blood, 2020, 136, 19-20.	0.6	2
28	Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices. Blood, 2020, 136, 14-15.	0.6	0
29	Real-World Clinical Outcomes in Previously Untreated and Minimally Treated Patients with Congenital Factor VIII Deficiency: The San Diego Experience. Blood, 2020, 136, 31-32.	0.6	1
30	Utilization of Telemedicine for Comprehensive Visits in Patients with Inherited Bleeding Disorders during the COVID-19 Pandemic. Blood, 2020, 136, 10-11.	0.6	1
31	U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis. Blood, 2020, 136, 39-40.	0.6	1
32	How we approach: Training pediatric coagulationists. Pediatric Blood and Cancer, 2019, 66, e27982.	0.8	1
33	Your tired, your poor, your huddled masses. Blood, 2019, 133, 2010-2011.	0.6	0
34	Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia, 2019, 25, 668-675.	1.0	38
35	Hematologic Manifestations of Nutritional Deficiencies: Early Recognition is Essential to Prevent Serious Complications. Journal of Pediatric Hematology/Oncology, 2019, 41, e182-e185.	0.3	4
36	Scurvy Findings in a Child with Jacobsen Syndrome. JBJS Case Connector, 2019, 9, e0352-e0352.	0.1	1

#	ARTICLE	IF	CITATIONS
37	A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor. <i>Haemophilia</i> , 2019, 25, e48-e50.	1.0	1
38	Electronic Health Record Tools to Promote Transition Readiness and Knowledge for Adolescents and Young Adults with Hemophilia. <i>Blood</i> , 2019, 134, 4685-4685.	0.6	0
39	Children with sickle cell disease migrating to the United States from sub-Saharan Africa. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27000.	0.8	8
40	Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003525.	0.5	10
41	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 209S-216S.	0.7	6
42	How I approach: Previously untreated patients with severe congenital hemophilia A. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27466.	0.8	4
43	Identification and characterization of novel mutations implicated in congenital fibrinogen disorders. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 800-811.	1.0	28
44	Risk factors for cardiovascular disease in children and young adults with haemophilia. <i>Haemophilia</i> , 2018, 24, 747-754.	1.0	10
45	The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 239-249.	1.1	23
46	A novel compound heterozygous form of severe protein C deficiency causing bleeding without purpura fulminans. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26626.	0.8	0
47	Venous Thromboembolism in Children with Cancer and Blood Disorders. <i>Frontiers in Pediatrics</i> , 2017, 5, 12.	0.9	19
48	Treatment adherence in hemophilia. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1677-1686.	0.8	117
49	Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1031-1037.	0.8	73
50	Ataxia telangiectasia presenting as hyper IgM syndrome without neurologic signs. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 221-226.	0.5	3
51	Effects of hydroxyurea treatment for patients with hemoglobin SC disease. <i>American Journal of Hematology</i> , 2016, 91, 238-242.	2.0	54
52	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 298-306.	1.0	14
53	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. <i>Journal of Pediatric Surgery</i> , 2016, 51, 122-127.	0.8	39
54	Increasing Quality Improvement Capability in a Hemophilia Treatment Center. <i>Blood</i> , 2016, 128, 5908-5908.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 73-73.	0.6	6
56	Hospital-Acquired Venous Thromboembolism in Children: Call-to-Action. <i>Journal of Pediatrics</i> , 2014, 165, 652-653.	0.9	3
57	Sickle cell anemia: time for personalized prescription of hydroxyurea? Focus on "Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics": <i>American Journal of Physiology - Cell Physiology</i> , 2013, 305, C1209-C1210.	2.1	1
58	Do Difficulties In Swallowing Medication Impede The Use Of Hydroxyurea In Children?. <i>Blood</i> , 2013, 122, 2967-2967.	0.6	1
59	Impact of hydroxyurea on clinical events in the BABY HUG trial. <i>Blood</i> , 2012, 120, 4304-4310.	0.6	204
60	Differences in Health-Related Quality of Life in Children With Sickle Cell Disease Receiving Hydroxyurea. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 251-254.	0.3	85
61	Hydroxyurea Treatment of Young Children with Sickle Cell Anemia: Safety and Efficacy of Continued Treatment " the BABY HUG Follow-up Study. <i>Blood</i> , 2011, 118, 7-7.	0.6	4
62	The Physiological and Clinical Effects of Interrupting a Treatment Regimen of Hydroxyurea in Young Children with Sickle Cell Anemia (SCA). <i>Blood</i> , 2011, 118, 2134-2134.	0.6	0
63	Adherence to study medication and visits: Data from the BABY HUG trial. <i>Pediatric Blood and Cancer</i> , 2010, 54, 260-264.	0.8	30
64	Adherence to Hydroxyurea Therapy in Children with Sickle Cell Anemia. <i>Journal of Pediatrics</i> , 2010, 156, 415-419.	0.9	138
65	Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA). <i>Blood</i> , 2010, 116, 270-270.	0.6	8
66	Complications of Implantable Venous Access Devices In Patients with Sickle Cell Disease. <i>Blood</i> , 2010, 116, 1649-1649.	0.6	0
67	Family Perceptions of Barriers and Facilitators of Treatment Protocols for Secondary Stroke Prevention in Children with Sickle Cell Disease. <i>Blood</i> , 2010, 116, 4805-4805.	0.6	0
68	A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. <i>Pediatric Blood and Cancer</i> , 2009, 52, 609-615.	0.8	82
69	Anticoagulation in children: personalized strategies. <i>Pediatric Health</i> , 2009, 3, 107-109.	0.3	2
70	Impact of Hydroxyurea On Peri-Operative Management and Outcomes in Children with Sickle Cell Anemia.. <i>Blood</i> , 2009, 114, 2567-2567.	0.6	1
71	The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites: Data From the Pediatric Registry.. <i>Blood</i> , 2009, 114, 2990-2990.	0.6	0
72	Risk for Post Thrombotic Syndrome (PTS) Development in Children with Extremity Deep Venous Thrombosis (DVT): Results of the US Centers for Disease Control and Prevention (CDC) Pediatric Thrombosis and Hemostasis Centers.. <i>Blood</i> , 2009, 114, 4000-4000.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters. <i>Thrombosis Research</i> , 2008, 122, 782-785.	0.8	55
74	Study Drug and Visit Adherence: Data from the BABY HUG Trial.. <i>Blood</i> , 2008, 112, 1275-1275.	0.6	4
75	Adherence with Hydroxyurea in Children with Sickle Cell Disease. <i>Blood</i> , 2008, 112, 167-167.	0.6	3
76	Efficacy of Hydroxyurea To Prevent Organ Damage in Young Children with Sickle Cell Anemia.. <i>Blood</i> , 2007, 110, 3386-3386.	0.6	5
77	Neonatal thromboembolic emergencies. <i>Seminars in Fetal and Neonatal Medicine</i> , 2006, 11, 198-206.	1.1	67
78	Heparin-induced thrombocytopenia and thrombosis syndrome in children. , 0, , 158-165.		0